Ocular Therapeutix, Inc.
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
About
CEO
Dr. Pravin U. Dugel M.D.
Employees
267
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
15 Crosby Drive, Bedford, MA 01730, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | — | — | — | — |
| Aug 5, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Mar 10, 2025 | — | — | — | — |
| Nov 14, 2024 | -0.24 | -0.22 | 0.02 | -8.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 5 |
| Average estimate | — | -0.25 | — | -1.02 |
| Low estimate | — | -0.27 | — | -1.09 |
| High estimate | — | -0.24 | — | -0.96 |
| Last year EPS | — | -0.24 | — | -1.07 |
[stock_revenue_estimate]
Growth estimates
Current qtr
37.140%
Next qtr. (Mar 2025)
-5.210%
Current year
-27.960%
Next year (Dec 2025)
4.000%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 58.44M | 51.49M | 43.52M | 17.40M | 4.23M |
| Cost of revenue | 5.28M | 4.54M | 4.41M | 2.08M | 2.33M |
| Gross profit | 53.16M | 46.95M | 39.12M | 15.32M | 1.90M |
| Operating expense | |||||
| Research & development | 61.06M | 53.46M | 50.08M | 28.69M | 41.09M |
| Selling general and admin | 74.49M | 72.15M | 67.07M | 49.47M | 46.61M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -82.38M | -78.65M | -78.04M | -62.85M | -85.80M |
| Non operating interest income | |||||
| Income | 3.98M | 798,000 | 33,000 | 168,000 | 1.23M |
| Expense | 11.34M | 7.02M | 6.67M | 6.77M | 6.10M |
| Other income expense | 9.00M | 13.84M | 78.12M | -86.19M | 4.30M |
| Pretax income | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M |
| Tax provision | — | — | — | — | — |
| Net income | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M |
| Basic EPS | -1.01 | -0.92 | -0.09 | -2.56 | -1.91 |
| Diluted EPS | -1.02 | -0.97 | -0.98 | -2.56 | -1.91 |
| Basic average shares | 79.83M | 76.88M | 76.39M | 60.75M | 45.27M |
| Diluted average shares | 79.83M | 76.88M | 76.39M | 60.75M | 45.27M |
| EBITDA | -75.42M | -75.75M | -75.58M | -59.91M | -82.05M |
| Net income from continuing op. | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 252.06M | 149.29M | 204.89M | 261.86M | 78.74M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 195.81M | 102.30M | 164.16M | 228.06M | 54.44M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 26.18M | 21.33M | 21.14M | 12.25M | 2.55M |
| Other receivables | — | — | — | — | — |
| Inventory | 2.31M | 1.97M | 1.25M | 1.20M | 954,000 |
| Prepaid assets | — | — | 4.75M | 4.65M | 2.23M |
| Restricted cash | 150,000 | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 7.79M | 4.03M | 4.75M | 4.65M | 2.23M |
| Non current assets | |||||
| Properties | 21.99M | 20.53M | 15.86M | 16.03M | 16.17M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.50M | 1.50M | 1.52M | 1.50M | 1.35M |
| Construction in progress | 281,000 | 4.07M | 578,000 | 120,000 | 239,000 |
| Leases | 14.70M | 9.07M | 9.07M | 9.07M | 9.07M |
| Accumulated depreciation | -20.26M | -17.28M | -15.21M | -12.79M | -10.02M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 1.61M | 1.76M | 1.76M | 1.76M | 1.76M |
| Total liabilities | 160.93M | 113.91M | 116.89M | 185.77M | 82.37M |
| Current liabilities | |||||
| Accounts payable | 4.39M | 5.12M | 4.59M | 2.71M | 3.27M |
| Accrued expenses | 28.67M | 24.10M | 20.12M | 14.31M | 7.64M |
| Short term debt | 1.59M | 1.60M | 1.62M | 9.65M | 1.13M |
| Deferred revenue | 255,000 | 576,000 | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 81.80M | 62.68M | 57.36M | 48.79M | 58.22M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 29.99M | 6.35M | 20.19M | 98.31M | 12.12M |
| Other non current liabilities | 108,000 | 93,000 | — | — | — |
| Shareholders equity | |||||
| Common stock | 12,000 | 8,000 | 8,000 | 8,000 | 5,000 |
| Retained earnings | -697.58M | -616.84M | -545.80M | -539.25M | -383.62M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 91.13M | 35.38M | 88.00M | 76.10M | -3.63M |
| Additional paid in capital | 788.70M | 652.21M | 633.80M | 615.34M | 379.98M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M | -59.98M | -63.39M | -44.70M | -39.75M | -28.65M | -13.32M | -14.09M |
| Depreciation | 2.98M | 2.11M | 2.42M | 2.77M | 2.53M | 2.29M | 1.63M | 881,000 | 754,000 | 547,000 | 404,000 | 404,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 17.83M | 16.96M | 14.98M | 7.53M | 8.76M | 7.48M | 7.32M | 5.96M | 4.64M | 2.64M | 476,000 | 243,000 |
| Other Non-Cash Items | 6.11M | 4.85M | 4.63M | 4.41M | 3.68M | 397,000 | 408,000 | 371,000 | 166,000 | 2.47M | 46,000 | 86,000 |
| Accounts Receivable | -4.85M | -190,000 | -8.88M | -9.70M | -2.35M | 25,000 | 24,000 | -57,000 | 136,000 | -60,000 | -224,000 | 77,000 |
| Accounts Payable | 583,000 | -621,000 | 1.80M | -452,000 | 124,000 | -796,000 | 932,000 | -159,000 | 348,000 | 507,000 | -174,000 | 145,000 |
| Other Assets & Liabilities | -147,000 | -207,000 | 570,000 | 11.44M | -115,000 | -95,000 | -9,000 | -21,000 | -147,000 | -195,000 | 250,000 | 8,000 |
| Operating Cash Flow | -58.24M | -48.13M | 8.96M | -139.64M | -73.74M | -50.68M | -53.09M | -37.73M | -33.85M | -22.74M | -12.54M | -13.13M |
| Investing Activities | ||||||||||||
| Capital Expenditures | -6.09M | -3.72M | -1.19M | -841,000 | -2.24M | -1.89M | -8.25M | -1.92M | -1.77M | -1.26M | -387,000 | -203,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | -3.00M | -41.70M | -91.68M | -37.33M | — | — |
| Sale of Investments | — | — | — | — | — | — | 38.20M | 80.68M | 54.83M | — | — | 4.02M |
| Investing Cash Flow | -6.09M | -3.72M | -1.19M | -841,000 | -2.24M | -1.89M | 27.07M | 35.57M | -38.57M | -38.59M | -387,000 | 3.81M |
| Financing Activities | ||||||||||||
| Long-Term Debt Issuance | 82.47M | — | 3.72M | 3.20M | 37.28M | 12.03M | 3.70M | — | 1.90M | 14.88M | — | 4.42M |
| Long-Term Debt Payments | -28.13M | — | -4.17M | -3.20M | — | -5.66M | -1.30M | — | -1.50M | -2.27M | -1.82M | -909,000 |
| Other Financing Charges | -5.18M | — | -275,000 | — | — | — | -591,000 | -519,000 | -762,000 | -3.25M | — | — |
| Financing Cash Flow | 166.43M | — | -720,000 | 224.68M | 74.81M | 67.95M | 31.05M | 108,000 | 65.64M | 91.48M | 6.68M | 30.80M |
| Other Cash Details | ||||||||||||
| End Cash Position | 197.57M | 104.06M | 165.93M | 229.82M | 56.20M | 60.68M | 43.15M | 34.66M | 30.78M | 37.39M | 17.51M | 23.85M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 5.46M | 2.15M | 1.93M | 2.35M | 2.30M | 1.52M | 1.46M | 1.30M | 1.25M | 844,000 | 289,000 | 216,000 |
| Free Cash Flow | -76.32M | -63.32M | -66.74M | -54.40M | -79.82M | -51.12M | -58.73M | -35.92M | -35.52M | -21.76M | -13.03M | -12.79M |
Error: Invalid format in Holders JSON file.
Article
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
Feb 3, 2025
Article
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 17, 2025
Article
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024
Jan 14, 2025
